Answers are grounded in this paper and cite their sources.
Sir, RA affects women more than men and often during childbearing years. Treatment during pregnancy is necessary to control maternal disease in favour of successful pregnancy outcome [1]. Rituximab, a chimeric immunoglobulin G1 (IgG1) monoclonal anti-CD20 antibody depletes circulating B cells and decreases RA activity [2]. Few data have been published concerning safety of rituximab during pregnancy. Placental passage of rituximab during the first trimester is minimal, significant during the second trimester and extensive in the third [3, 4], and may affect fetal and neonatal B-cell development, potentially leading to increased susceptibility to infections. Studies in cynomolgus monkeys exposed during pregnancy to therapeutic doses of rituximab showed no evidence of teratogenic effects. However, B cells were reduced in the offspring and returned to normal within 6 months after birth [5]. Since human studies are lacking, data from animal studies are insufficient, and rituximab is detectable in serum for up to 6 months, women of childbearing age are advised to use contraception during treatment and 12 months thereafter [6]. We describe the first case in RA of maternal rituximab exposure shortly before conception and present a review of cases with exposure to rituximab during pregnancy. A 32-year-old woman with RA since 2000 was unsuccessfully treated with DMARD monotherapy and combination with TNF-α blockers. Due to active RA [28-joint DAS (DAS-28): 5.32], she was treated with rituximab under good clinical response (DAS-28: 2.99). She reported pregnancy, established 6 weeks after rituximab infusion, despite use of oral contraceptive. Following an uncomplicated pregnancy of 37 weeks, she delivered girl twins. One had a clubfoot, the other transient erythema toxicum neonatorum (ETN); otherwise, they were healthy. Post-partum normal B-cell counts and normal immunoglobulin levels were measured. Transient mild leucocytosis occurred in the girl with ETN, without signs of infection. Other haematological tests were normal. During 8 months of follow-up, normal B-cell counts and immunoglobulin levels were measured. Both girls developed normally, although one suffers from mild asthma, without serious infectious complications. A PubMed literature search was performed using search terms rituximab and pregnancy; only articles in English with full text available were included. Nine case reports of rituximab administration during pregnancy were identified and, in an update, three additional cases were described [7]. Characteristics and outcome of 13 pregnancies (including our case) are summarized in Table 1. Summary of case reports AIHA: auto-immune haemolytic anaemia; TTP: thrombotic thrombocytopenic purpura; GC: glucocorticoid; CS: Caesarean section; VD: vaginal delivery; FU: follow-up. Summary of case reports AIHA: auto-immune haemolytic anaemia; TTP: thrombotic thrombocytopenic purpura; GC: glucocorticoid; CS: Caesarean section; VD: vaginal delivery; FU: follow-up. Rituximab is registered for treatment of non-Hogdkin lymphoma (NHL) and RA. Expansion of the area of indication (within the field of autoimmune diseases) is to be expected. Little has been published on the safety of rituximab during pregnancy. As shown in Table 1, underlying motherly disease, time of administration and co-medication vary largely. Despite different dosing regimes, the cumulative doses of rituximab are comparable. Not in all cases neonatal B-cell counts were performed. In this limited number of cases no relation could be found between underlying disease and abnormal neonatal B-cell counts. Relation between timing of administration and decreased neonatal B-cell counts is suspected, based on the knowledge that rituximab passes the placental barrier in the second and even more so in the third trimester [3, 4]; in three of four cases of B-cell depletion, rituximab was administered in the second and third trimester; in three cases of normal neonatal B cells, rituximab was administered before the second trimester; and, in one case, neonatal B-cell depletion occurred after administration in the first trimester. It might be speculated that rituximab levels persisted in this patient. In five cases, rituximab was combined with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP), resulting in neonatal B-cell abnormalities in two cases. Case reports, although limited in number, have shown no increased risk of fetal abnormalities when CHOP was administered during pregnancy [8]. Hence, the observed B cell might be contributed to rituximab rather than to CHOP. Moreover, two cases of neonatal B-cell abnormalities concerning NHL were treated with rituximab monotherapy, and ITP treated with rituximab in combination with IVIG. Fortunately, all affected infants showed recovery in B-cell counts without infectious complications. This favourable outcome might be due to B-cell precursors, unaffected by rituximab, causing quick recovery of the B cells in newborns. Maternal immunoglobulins, which cross the placenta, will protect neonates from infectious complications early in life. Neonatal immunoglobulin levels seemed not to be influenced by exposure to rituximab during pregnancy, as response to vaccination, a natural test for B-cell function, was reported normal in all cases tested. In the presented twin pregnancy, rituximab was administered 6 and 8 weeks before conception without adverse events for the newborns. In line with this, Ostensen mentioned in an unpublished safety report 10 pregnancies exposed to rituximab 1–8 months before conception with no congenital abnormalities or serious neonatal or early childhood infections. No data were available on neonatal B-cell counts. Although further investigation on safety of rituximab before and during pregnancy is needed, our case, together with the unpublished, suggests that rituximab given shortly before conception does not have serious effects on the newborn. In addition, although still limited in number, nine published cases describing rituximab administration during pregnancy all had favourable outcome for the newborns. Disclosure statement: J.W.J.B. receives research support from Roche. All other authors have declared no conflicts of interest.
No takes yet. Share an insight, caveat, or question.
Ton et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: